Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Study Design: Treatment, Randomized, Open Label, Parallel Assignment This study is an open
randomized and controlled trial aiming at assessing the efficacy and safety of Idarubicin
(IDA) at different doses of 8mg/m2 and 10mg/m2 combined with cytarabine as induction therapy
for newly diagnosed Acute Myeloid Leukaemia (AML). All the recruited patients are allocated
to group A ( 8mg/m2 group) or group B ( 10mg/m2) in random. It is advised that induction
therapy should begain not late than 3 days after randomization. The regimens in detail can be
refered in the therapy protocol.
Phase:
Phase 4
Details
Lead Sponsor:
Guangdong General Hospital Guangdong Provincial People's Hospital